Alex Karnal, co-founder and CIO of Braidwell, a life sciences investment firm, spent 20 years building and backing biotech ...

Avalyn Pharma is hoping to rake in around $182 million from an IPO, which the biotech will use to take its inhaled versions ...

The high-profile obesity drug developer priced the biotech sector’s biggest offering in years and will use the proceeds to ...

The startup is developing “modified DNA” therapies it claims can combine the strengths of multiple approaches, from messenger ...

Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend on to treat autoimmune diseases or cancers. The Food and Drug ...

Biotech has reasserted itself over the past year as drug approvals, obesity and GLP-1 programs, oncology pipelines, and ...

The promise of a better pan-RAS inhibitor Erasca has been described as the poor man’s Revolution Medicines. Impoverished ...

Following its recently announced partnership with Novo Nordisk, OpenAI is introducing a new reasoning model, GPT-Rosalind, to ...

Doubling survival in pancreatic cancer, a long-fought rare disease approval, a massive IPO and ambitious biotech ...